Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 67   

Articles published

ARNA 3.92
price chart
A Valuation Model For Arena's Belviq
With Arena Pharmaceuticals' (ARNA) Belviq finally approved, Arena will be transitioning from being a cash-starved biotech into an earnings-generating one.
Buy Arena Before European Approval Comes Through
Arena Pharmaceutical (NASDAQ:ARNA), a company operating in the healthcare sector, is involved in developing and commercializing drugs that target 'G-protein coupled receptors'.
3 Reasons to Buy VIVUS  DailyFinance
Arena Buyout Rumors Are Overblown
What happens when a small pharmaceutical company hitches its wagon to a drug that finally gains FDA approval? The stock runs, and images of dollars raining down upon the smart early investors cloud reality.
Insider Sales: Arena Pharmaceuticals, VIVUS Inc, Amarin Corporation
There has been an interesting trend among three noteworthy pharmaceutical companies like Arena Pharmaceuticals, Inc.
Vivus Looks Into European Approval As Company Pins Hopes On Qsymia  Seeking Alpha
Will pill-popping beat obesity?  Stuff.co.nz
The Potential Market For Arena's Belviq
... because the product the company we invest in has real potential. There is a substantial difference between potential market and the real market for any given product.
What Slims Down Fastest After Diet Drugs Are Approved by he FDA? Two Stocks ...  YCharts
Arena: Was This Pharmaceutical Stock a Pump and Dump?
These companies cannot be judged on their balance sheet because future earnings depend on FDA approval and successful sales and marketing.
Short Interest in Biotech Firms on the Rise
Short interest data has been released from the August 15 settlement date. Overall short sellers have continued to bet on biotech firms compared to the July 31 settlement date.
5 Bio-Pharma Stocks To Buy Right Here
Biotechnology and drug stocks offer some of the best potential for big gains in the market. The flip side of that proverbial coin, of course, is a great deal of risk.
How Much Can Vivus, Arena Pharma Charge for Diet Pills?
Lief told investors on a conference call that his company's partnership with Eisai is one of the reasons he feels confident about his drug's chances for success.
Simple Math Showing Why Synergy Pharmaceuticals Is Undervalued
In prior articles I've talked about Synergy Pharmaceuticals (NASDAQ:SGYP) as a fantastic under-the-radar biotech stock for 2012.